Welcome to our dedicated page for Insmed SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc senior vice president Samuele Butera received new equity awards as part of his compensation. He was granted 7,342 Restricted Stock Units, each representing one future share of common stock, with 25% vesting on the first day of the first month after the first anniversary of grant and the remainder vesting in three annual installments.
He was also granted stock options for 12,570 shares of common stock at an exercise price of $102.15 per share, expiring on June 23, 2036. These options vest 25% on the initial vesting date and 12.5% every six months thereafter until fully vested. All awards were granted for no cash consideration.
INSMED Inc executive files initial insider report with no transactions. Samuele Butera, listed as SVP, GM, Global Respiratory at INSMED Inc, is identified as a reporting person on a Form 3. The filing shows zero buy, sell, acquisition, or disposition transactions, and no derivative positions or holdings are reported.
INSMED Inc Chief Legal Officer Michael Alexander Smith sold 1,806 shares of Common Stock in an open-market transaction. The shares were sold at a price of $95.82 per share. After this sale, he directly holds 37,648 shares of INSMED Inc Common Stock.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which means the timing and amount were set in advance rather than decided at the moment of sale.
INSM filed Form 144 disclosing proposed sales of Common Stock by an insider and issuer stock plan activity. The filing lists multiple proposed dispositions by Michael Smith: 1,959 (appears as 1,959?), sorry—must use exact counts from the excerpt: the excerpt shows sale entries of 2,159 on 06/03/2026, 6,149 on 05/22/2026, 4,109 on 05/13/2026, and 19,638 on 03/30/2026. The filing also records stock plan activity dated 06/01/2026. These entries are disclosures of planned or reported dispositions; cash‑flow treatment and prices are not included in the excerpt.
INSMED Inc Chair and CEO William Lewis reported an open-market sale of 6,515 shares of Common Stock. The shares were sold at a price of $94.03 per share. After this transaction, he directly holds 258,917 shares of Common Stock.
The filing also shows an indirect holding of 233,924 shares of Common Stock held by a trust. According to a footnote, the sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025, indicating it was scheduled in advance.
INSM reported a Form 144 notice reporting proposed sales of Common Stock by William Lewis. The filing lists multiple proposed sale dates and quantities, including 7,605 shares on 06/03/2026 and 25,564 shares on 05/18/2026. The entries show share counts tied to each sale row and resulting share figures on the same lines.
INSM reported officer stock sale transactions under Rule 144. The filing lists recent dispositions of Common Stock executed through Merrill Lynch on 06/01/2026 and shows multiple seller entries for Martina Flammer. Examples include sales on 06/03/2026 (2,566 shares), 05/14/2026 (10,479 shares) and 05/13/2026 (7,854 shares). The submission uses a broker-dealer address in Washington, D.C., and is recorded on 06/05/2026.
INSMED Inc Chief Operating Officer Roger Adsett reported a sale of 2,370 shares of common stock. The shares were sold at an average price of $102.27 per share to satisfy tax withholding obligations related to the vesting of Restricted Stock Units and to cover associated broker fees. After this transaction, Adsett directly holds 98,603 shares of INSMED common stock, indicating this was a routine, tax-driven disposition rather than a discretionary reduction in his equity stake.
Insmed Inc.’s Chief Financial Officer Sara Bonstein reported an automatic sale of shares tied to equity compensation. On the reported date, 2,404 shares of common stock were sold at $102.27 per share. According to the footnote, the shares were sold to satisfy tax withholding obligations when Restricted Stock Units vested and to cover related broker fees, rather than as a discretionary portfolio move. After this transaction, Bonstein directly owned 69,082 Insmed shares, so the filing mainly reflects routine tax handling on stock-based compensation.
INSMED Inc Chief Legal Officer Michael Alexander Smith reported an open-market sale of company stock mainly to cover taxes on vesting equity.
He sold 2,159 shares of Common Stock at $102.27 per share to satisfy tax withholding obligations from vested Restricted Stock Units and related broker fees. After this transaction, he directly holds 39,454 shares, so the sale represents only a portion of his overall stake and is characterized as a tax-related, administrative transaction rather than a discretionary reduction in ownership.